Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

Ji Wu, Feng Meng, Henry Lu, Ling Kong, William Bornmann, Zhenghong Peng, Moshe Talpaz, Nicholas J. Donato

Blood (2008) 111 (7): 3821–3829.

https://doi.org/10.1182/blood-2007-08-109330

Published: 2008

Journal Articles

A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.

Alfonso Quintas-Cardama, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Ji Wu, Feng Meng, Nicholas Donato, PhD

Blood (2006) 108 (11): 4773.

https://doi.org/10.1182/blood.V108.11.4773.4773

Published: 2006

Journal Articles

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

Ji Wu, MD, Feng Meng, M.D., Moshe Talpaz, M.D., Nicholas J. Donato, PhD

Blood (2006) 108 (11): 2132.

https://doi.org/10.1182/blood.V108.11.2132.2132

Published: 2006

Journal Articles

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Nicholas J. Donato, PhD, Ji Wu, MD, Ling-Yuan Kong, MD, PhD, Feng Meng, MD, Francis Lee, PhD, Moshe Talpaz, MD

Blood (2005) 106 (11): 1087.

https://doi.org/10.1182/blood.V106.11.1087.1087

Published: 2005

Journal Articles

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Nicholas J. Donato, PhD, Ji Wu, MD, Ling Y. Kong, MD, PhD, Feng Meng, MD, Waldemar Priebe, PhD, Moshe Talpaz, MD

Blood (2004) 104 (11): 2964.

https://doi.org/10.1182/blood.V104.11.2964.2964

Published: 2004

NARROW

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.

Lyn Kinase Alters Gab2 Phosphorylation and c-Cbl Protein Levels To Regulate Imatinib Sensitivity and Survival of Chronic Myelogenous Leukemia Cells.

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only